Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Matthew D'onofrio Insider Profile
4 Followers
Matthew D'onofrio, CEO, Director at Evoke Pharma, holds 284.00K shares in Evoke Pharma (Ticker: EVOK). Most recently, Matthew D'onofrio Sold $46,000 shares of Evoke Pharma on Dec 14, 2020 for an estimated value of 134.09K.
Matthew D'onofrio has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Matthew D'onofrio's holdings
Insider Roles
CEO, Director
Roles that Matthew D'onofrio holds in companies
Most Profitable Insider Trade
The most profitable trade made by Matthew D'onofrio
Matthew D'onofrio's Trading History
List of latest transactions for each holding click on a transaction to see Matthew D'onofrio's performance on stock
You May Also Like
Matthew D'onofrio insider profile FAQ
What is the percentage of profitable transactions made by Matthew D'onofrio?
The percentage of profitable transactions made by Matthew D'onofrio is ―.
What is the average return per transaction made by Matthew D'onofrio?
The average return per transaction made by Matthew D'onofrio is ―.
What stocks does Matthew D'onofrio hold?
Matthew D'onofrio holds: EVOK stocks.
What was Matthew D'onofrio’s latest transaction?
Matthew D'onofrio latest transaction was an Informative Sell of $134.09K.
What was Matthew D'onofrio's most profitable transaction?
Matthew D'onofrio’s most profitable transaction was an Informative Sell of EVOK stock on December 14, 2020. The return on the trade was 78.30%.
What is Matthew D'onofrio's role in Evoke Pharma?
Matthew D'onofrio's role in Evoke Pharma is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.